Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.6102 +0.0001 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
33 34 Next >
OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today
Ocugen (OCGN) stock is on the move today as traders on social media push the company higher in a new rally for the shares. 
Via InvestorPlace
Why Are Ocugen Shares Surging On Monday?
According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc... 
Via Benzinga
Exposures COVID-19
45 Stocks Moving In Monday's Mid-Day Session
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
Exposures COVID-19
This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla
An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes. Since January 2021, Ocugen stock's year-to-date return has outperformed a number... 
Via Benzinga
Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved
There's no revenue yet for Ocugen, but OCGN stock could be worth 19% higher if its Covid-19 vaccine gets the thumbs up. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Will Suffer Its Inevitable Demise Sooner Rather Than Later
At some point, the music will stop for OCGN stock, but for now, there's still plenty at play to keep it at inflated prices. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Seems Unattractive With Regulatory Uncertainties
OCGN stock is unattractive as regulatory approval delays have limited the revenue and cash flow potential for the Covid-19 vaccine. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Doesn’t Have Short-Term Catalysts Needed To Make It a Buy
OCGN stock is interesting once again as concerns regarding the Delta variant mount. But that should not be your sole reason to invest in Ocugen. 
Via InvestorPlace
Exposures COVID-19
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution. 
Via InvestorPlace
The Odds Are Firmly Against Ocugen Stock Now
OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts. 
Via InvestorPlace
Exposures COVID-19 Product Safety
2 Popular Robinhood Stocks I Wouldn't Buy With Free Money
Not every stock on the popular trading app is worth owning. 
Via The Motley Fool
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
Cynicism and Conspiracy Theories Could Help Ocugen
While OCGN stock seems well behind the vaccination race to be worth a shot, there is one narrative that could potentially help. 
Via InvestorPlace
Exposures COVID-19
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
Ocugen’s Facing a Major Uphill Climb Without FDA Approval
OCGN stock will be hard pressed to push any higher in the absence of good news 
Via InvestorPlace
Exposures Product Safety
Ocugen Stock Is Well-Positioned, But Investors Want Results
The company's latest business update sounds all fine and good, but OCGN stock holders want to see some action, not just words. 
Via InvestorPlace
Exposures COVID-19
Ocugen Stock Still Looks Poised to Tumble
Ocugen's apparent failure to prepare a U.S. trial for Covaxin, which will likely be necessary for FDA approval, bodes badly for OCGN stock. 
Via InvestorPlace
Exposures Product Safety
Ocugen Stock Remains an All or Nothing Wager You Shouldn’t Make
With limited upside from both its booster shot and Canada EUA catalysts, it's still best to avoid/sell OCGN stock. 
Via InvestorPlace
Exposures COVID-19
Analyzing Ocugen's Unusual Options Activity
Ocugen (NASDAQ:OCGN) shares experienced unusual options activity on Thursday. The stock price moved down to $6.92 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
LAWSUITS FILED AGAINST OCGN, DKNG and PLL - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal Product Safety
CLASS ACTION UPDATE for OCGN, HMPT and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal Product Safety
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, OCGN and OTLY
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies.... 
From The Gross Law Firm
Via AccessWire
Exposures Product Safety
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, AHCO and ATVI
NEW YORK, NY / ACCESSWIRE / August 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies.... 
From The Gross Law Firm
Via AccessWire
Exposures Product Safety
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
LAWSUITS FILED AGAINST OCGN, DKNG and BZ - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / August 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal Product Safety
Ocugen Now Relies Solely on A Continued COVID-19 Crisis
OCGN stock is a mix of irrational exuberance related to its valuation, unrealistic hopes, continuous speculation and very poor fundamentals. 
Via InvestorPlace
Exposures COVID-19
CLASS ACTION UPDATE for OCGN, REKR and BLCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal Product Safety
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.